Fundraising FoxIkarian Capital — 2026 Investments
2 investments dated 2026 · listed companies and verified rows first · show all
Jasper Therapeutics develops briquilimab, a targeted anti-KIT monoclonal antibody designed to deplete mast cells for treating chronic immunological and inflammatory diseases.
BiotechHealthtechRedwood City, US
Judith Shizuru(Director)Herb Cross(Executive Officer)inJeet Mahal(Executive Officer, Director)inPatrick Crutcher(Director)Svetlana Lucas(Director)Wenru Song(Executive Officer)
Co-investorsAvego BioScience CapitalQiming Venture Partners USATSVCAbingworth
Kira Pharmaceuticals is a biotech company developing therapies targeting complement biology to treat complement-mediated diseases.
BiotechHealthtechCambridge, US
Wenru Song(Founder)in
Co-investorsForesite CapitalQuan CapitalVivo Capital
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.